This commentary provides an overview of the 2024 Association of Multidisciplinary Education and Research in Substance Use and Addiction annual conference: Empowering Change: From Evidence to Action in Addiction Care and Research, held from November 14 to 16, 2024, in Chicago. The conference featured 16 interactive workshops, 166 oral abstract presentations, and 120 poster presentations. From the preconference workshop to plenary sessions, paper, and poster presentations, there was a focus on practical approaches to implementing evidence-based practices in a variety of settings.
EcclesMPWeijerCMittmanB.Requirements for ethics committee review for studies submitted to Implementation Science. Implement Sci. 2011;6:1-3.
3.
MetzAAlbersBBurkeK, et al. Implementation practice in human service systems: understanding the principles and competencies of professionals who support implementation. Hum Serv Organ Manag Leadersh Gov. 2021;45(3):238-259.
4.
SametJHGalanterMBriddenCLewisDC.Association for medical education and research in substance abuse. Addiction. 2006;101(1):10-15. doi:10.1111/j.1360-0443.2005.01228.x
5.
LewisDSchnollSH.Commentary on the 40th anniversary of AMERSA: AMERSA at 40: how it all began and how it survived. Subst Abus. 2018;39(2):134-138. doi:10.1080/08897077.2018.1495892
DunhamKHillKKazalH, et al. In support of overdose prevention centers: position statement of AMERSA, Inc (Association for Multidisciplinary Education and Research in Substance Use and Addiction). Subst Use Addict J. 2024;45(3):328-336.
8.
WHO Guideline: consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations; 2022. Accessed December 16, 2024. https://www.who.int/publications/i/item/9789240052390
9.
Substance Abuse and Mental Health Services Administration. SAMHSA announces unprecedented $30 million harm reduction grant funding opportunity to help address the nation’s substance use and overdose epidemic. 2021. Accessed December 16, 2024. https://www.samhsa.gov/newsroom/press-announcements/202112081000
Substance Abuse and Mental Health Services Administration: Harm Reduction Framework. Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration, 2023. Accessed Harm Reduction Framework on 1/1/2025.
12.
GiglioREManthaSHarocoposA, et al. The nation’s first publicly recognized overdose prevention centers: lessons learned in New York city. J Urban Health. 2023;100(2):245-254.
13.
OnPoint NYC—Making History Savings Lives. Published December12, 2014. Accessed January 2, 2025. www.onpointnyc.org.
14.
SeeK.Making history, saving lives. Paper presented at: AMERSA 2024 Plenary Presentation; November 14, 2024; Chicago, IL.
15.
ParkJNTardifJThompsonERosenJGLiraJASGreenTC.A survey of North American drug checking services operating in 2022. Int J Drug Policy. 2023;121:104206. doi:10.1016/j.drugpo.2023.104206
16.
Street Check Community Drug Checking Program. Accessed January 2, 2025. www.streetcheck.org
17.
ParkJNSerafinskiRUjenezaM, et al. Xylazine awareness, desire, use and exposure: preliminary findings from the Rhode Island community-based drug checking cohort study. Drug Alcohol Depend Rep. 2024;11:100247.
VestNFlesakerMBohlerR, et al. Characterizing Collegiate Recovery Programs in the US and Canada: a survey of program directors. J Stud Alcohol Drugs. 2024. Published online October 23, 2024. doi:10.15288/jsad.24-00207
KaplowJBLayneCMPynoosRSCohenJALiebermanA.DSM-V diagnostic criteria for bereavement-related disorders in children and adolescents: developmental considerations. Psychiatry. 2012;75(3):243-266. doi:10.1521/psyc.2012.75.3.243. Erratum in: Psychiatry. 2012 Winter;75(4):398.
23.
D’OnofrioGO’ConnorPGPantalonMV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-1644. doi:10.1001/jama.2015.3474
24.
D’OnofrioGEdelmanEJHawkKF, et al. Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder. JAMA Netw Open. 2023;6(4):e235439. doi:10.1001/jamanetworkopen.2023.5439
25.
O’ConorCFarhiSCowanEFitzgeraldR. Inpatient initiation of long-acting injectable buprenorphine at a community hospital: a retrospective case series. J Addict Dis. 2024:1-7. Published online September 1, 2024. doi:10.1080/10550887.2024.2391145
26.
StrongAWallaceTSaiM.Local hot topics plenary: improving access to addiction treatment. Paper presented at: AMERSA 2024 Plenary Presentation; November 14, 2024; Chicago, IL.
27.
NeebCMcQuadeBMLesondakL, et al. Integration of a community opioid treatment program into a federally qualified health center. J Addict Med. 2024;18(6):663-669. doi:10.1097/ADM.0000000000001336
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2022 National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2023. Accessed January 2, 2025. https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report
30.
WhiteAM.Gender differences in the epidemiology of alcohol use and related harms in the United States. Alcohol Res. 2020;40(2):01. doi:10.35946/arcr.v40.2.01
31.
ErolAKarpyakVM.Sex and gender-related differences in alcohol use and its consequences: contemporary knowledge and future research considerations. Drug Alcohol Depend. 2015;156:1-13. doi:10.1016/j.drugalcdep.2015.08.023
32.
ChartierKCaetanoR.Ethnicity and health disparities in alcohol research. Alcohol Res Health. 2010;33(1-2):152-160.
33.
KeyesKMHatzenbuehlerMLGrantBFHasinDS.Stress and alcohol: epidemiologic evidence. Alcohol Res. 2012;34(4):391-400.
34.
RoseAKJonesA.Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction. 2018;113(8):1396-1406. doi:10.1111/add.14191
35.
BschorTHensslerJMüllerMBaethgeC.Baclofen for alcohol use disorder-a systematic meta-analysis. Acta Psychiatr Scand. 2018;138:232-242. doi:10.1111/acps.12905
36.
RayLAGreenREndersC, et al. Efficacy of combining varenicline and naltrexone for smoking cessation and drinking reduction: a randomized clinical trial. Am J Psychiatry. 2021;178:818-828.
37.
NietoSJEndersCKWitkiewitzKO’MalleySSRayLA.Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels. Alcohol Clin Exp Res. 2022;46(12):2258-2266. doi:10.1111/acer.14953
38.
ChuongVFarokhniaMKhomS, et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023;8(12):e170671.
39.
WangWVolkowNDBergerNA, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024;15:4548. doi:10.1038/s41467-024-48780-6
40.
GreenfieldBLRoosCHaglerKJSteinEBowenSWitkiewitzKA.Race/ethnicity and racial group composition moderate the effectiveness of mindfulness-based relapse prevention for substance use disorder. Addict Behav. 2018;81:96-103. doi:10.1016/j.addbeh.2018.02.010
GoldstickJECunninghamRMCarterPM.Current causes of death in children and adolescents in the United States. N Engl J Med. 2022;386(20):1955-1956. doi:10.1056/NEJMc2201761
43.
FriedmanJGodvinMShoverCLGoneJPHansenHSchrigerDL.Trends in drug overdose deaths among US adolescents, January 2010 to June 2021. JAMA. 2022;327(14):1398-1400. doi:10.1001/jama.2022.2847
44.
MarschLAMooreSKBorodovskyJT, et al. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction. 2016;111(8):1406-1415. doi:10.1111/add.13363
45.
WoodyGEPooleSASubramaniamG, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003-2011. doi:10.1001/jama.2008.574
46.
TerranellaAGuyGPMikoszC.Buprenorphine dispensing among youth aged ≤19 years in the United States: 2015-2020. Pediatrics. 2023;151(2):e2022058755. doi:10.1542/peds.2022-058755
47.
KingCBeethamTSmithN, et al. Treatments used among adolescent residential addiction treatment facilities in the US, 2022. JAMA. 2023;329(22):1983-1985. doi:10.1001/jama.2023.6266
48.
AllamiNO’ConnorKBagleySM.A case of severe opioid and methamphetamine use disorder in a 14 year old. Addict Sci Clin Pract. 2024;19:54. doi:10.1186/s13722-024-00487-1
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
